BioSpace News Archive

Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that that it will issue its Third Quarter 2023 Financial Results on November 29, 2023.

Boehringer Ingelheim, a global leader in animal health, has received marketing authorization from the European Commission for SENVELGO®, marking a significant step for the treatment of feline diabetes in Europe.

MC2 Therapeutics announced that the first patients have been enrolled in a Phase 2 PoC trial evaluating the safety and efficacy of MC2-25 VLS, an innovative new drug candidate for the treatment of urea associated skin diseases, incl.

CN Bio, a leading Organ-on-a-Chip company that designs and manufactures single-and multi-organ microphysiological systems, has received the ‘Most Impactful Industry Collaboration of the Year’ at the 2023 OBN Awards.

Sensorion is pleased to announce that its management team, including Chief Executive Officer Nawal Ouzren, will be attending the 42nd Annual J.P. Morgan Healthcare Meeting, taking place on January 08-11, 2024, in San Francisco, USA.

Simcere Pharmaceutical Group Limited entered into an exclusive license and collaboration agreement with Connect Biopharma HongKong Limited in relation to Rademikibart, an innovative IL-4Rα monoclonal antibody.

Neurophet, an artificial intelligence solution company for brain disease, announced on the 23rd that Neurophet would participate in the Radiological Society of North America 2023.

Vertex Pharmaceuticals Incorporated announced that the European Commission has granted approval for the label expansion of KAFTRIO® in a combination regimen with ivacaftor for the treatment of children with cystic fibrosis ages 2 through 5 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.

Broncus is pleased to announce that, on November 23 2023 Broncus Hangzhou has entered into the Equity Transfer Agreement with the shareholders of the Hangzhou Jingliang, to acquire 100% equity interest in it.

Medicure Inc. announced that the FDA provides complete approval to enroll patients in its pivotal Phase 3 clinical trial to evaluate the use of its investigational product MC-1 for treatment of a rare pediatric disease called pyridoxine 5′-phosphate oxidase deficiency.